- cafead Sep 17, 2024 at 11:32: PM
via Merit Medical has revealed positive six-month data from a trial investigating its endoprosthesis in dialysis patients who require an arteriovenous fistula (AVF).
The results, which were presented at the Cardiovascular and Interventional Radiological Society of Europe (CIRSE), demonstrate that the US company’s device led to an 89.9% target lesion primary patency at six months.
article source
The results, which were presented at the Cardiovascular and Interventional Radiological Society of Europe (CIRSE), demonstrate that the US company’s device led to an 89.9% target lesion primary patency at six months.
article source